Here are eight points:
1. The market is anticipated to grow at a compound annual growth rate of 23.7 percent between 2016 and 2021.
2. More regenerative medicine research in orthopedic musculoskeletal spine and dermatology will grow the market.
3. Pharmaceutical and biotechnology company investments in regenerative medicines will also spur market growth, especially in cell therapies and immunotherapy.
4. North America dominates the global market, with the United States accounting for the highest market share.
5. Europe follows close behind North America in terms of market share, with Germany dominating.
6. Hefty investments and limited experienced professionals in the regenerative medicine field will hinder market growth.
7. Companies in the space are creating cell-based therapies, biologics, tissue-engineered cells and materials and implantable devices.
8. Celgene, Acelity, StemCells and Organogenesis lead the regenerative medicine market.
More articles on spine:
Drs. Jeff Lehmen, Steven Cyr & more: 6 spine surgeons in the headlines this week — July 29, 2016
Do PEEK rods lead to better spinal fusion? 5 key notes
UMass Memorial Medical Center becomes Blue Distinction Center for Spine Surgery: 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.